Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
2Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
Phio Pharmaceuticals Corp. (PHIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
4Distinct source URLs
8High confidence
0.845Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Phio Pharmaceuticals Corp. Suppliers
Ticker
Name
Confidence
Evidence
AGONOX
AGONOX
92%
Per the terms of the Clinical Co-Development Agreement, the Company agreed to reimburse AgonOx up to $ 4,000,000 in expenses incurred to conduct a Phase 1 clinical trial of PH- 762 treated DP TIL in …
H-C-WAINWRIGHT-CO-LLC
H-C-WAINWRIGHT-CO-LLC
92%
On April 8, 2026, Phio Pharmaceuticals Corp. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Sales Agent…
U-S-MANUFACTURER
U-S-MANUFACTURER
92%
Phio Pharmaceuticals Corp. has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply.
TRITON-FUNDS-LP
TRITON-FUNDS-LP
90%
the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 862,500 shares of Common Stock
ADVANCED-RNA-TECHNOLOGIES-LLC
ADVANCED-RNA-TECHNOLOGIES-LLC
85%
Advirna assigned to the Company its existing patent and technology rights related to the INTASYL technology in exchange for an annual maintenance fee of $ 100,000
Phio Pharmaceuticals Corp. Customers
Ticker
Name
Confidence
Evidence
MIRIMMUNE-LLC
MIRIMMUNE-LLC
62%
warded is based upon the Company’s closing stock price at the grant date and is expensed over the requisite service period. The following table summarizes the activity of the Company’s RSUs for the t…
OVERVIEW-PHIO-PHARMACEUTICALS-CORP
OVERVIEW-PHIO-PHARMACEUTICALS-CORP
62%
warded is based upon the Company’s closing stock price at the grant date and is expensed over the requisite service period. The following table summarizes the activity of the Company’s RSUs for the t…
Phio Pharmaceuticals Corp. Debt Obligations
Instrument
Description
Confidence
Evidence
PHIO-DEBT-11769
Warrants outstanding: 2.86
90%
xbrl warrant detail from xbrl 2026-03-31.
PHIO-DEBT-11770
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
Phio Pharmaceuticals Corp. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Phio Pharmaceuticals Corp..
Phio Pharmaceuticals Corp. Ownership
Holder
Name
Confidence
Evidence
PHIO-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 25 tracked holders.
